Danish pharmaceutical firm Novo Nordisk has elected Brian Daniels as a new member of its board of directors.
He brings over 20 years of pharmaceutical management expertise to the board, having served as director of immunology at MSD and vice president of immunology then senior vice president of global development and medical affairs at Bristol-Myers Squibb.
Currently, Daniels serves as a senior advisor to the Boston Consulting Group and a venture partner for 5AM Venture Management, both of which are based in the US.
In a statement, Novo Nordisk’s board of directors said it had recommended Daniels because of “his extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas”.
Novo Nordisk also announced the re-election of Goran Ando, Jeppe Christiansen, Bruno Angelici, Sylvie Gregoire, Liz Hewitt and Mary Szela to the board of directors.
The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.
The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.
“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.